Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STADOL PRESERVATIVE FREE vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Butorphanol is a synthetic agonist-antagonist opioid analgesic that exerts its effects primarily through binding to kappa-opioid receptors and, to a lesser extent, mu-opioid receptors, producing analgesia and sedation. It also has partial antagonist activity at mu receptors.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Management of pain (moderate to severe),Preoperative or preanesthetic medication,Supplement to balanced anesthesia,Relief of pain during labor
Mild to moderate pain,Fever
0.5–2 mg intravenously or intramuscularly every 3–4 hours as needed for pain. Alternatively, 1–2 mg as a single dose, may repeat in 30–60 minutes if needed.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life is 2.5–3.3 hours in adults; prolonged to 4–6 hours in elderly or hepatic impairment.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily metabolized in the liver to hydroxylbutorphanol via CYP3A4 and other enzymes.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily hepatic metabolism (glucuronidation) to inactive metabolites; renal excretion accounts for <5% unchanged drug. Approximately 70% of dose excreted in urine as metabolites, 20% in feces.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Approximately 76–80% bound to serum proteins, primarily albumin and α1-acid glycoprotein.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Volume of distribution is 1.2–1.7 L/kg, indicating extensive tissue distribution.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Intramuscular: 70–80%; Subcutaneous: similar to IM. Oral: <5% due to extensive first-pass metabolism.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
For GFR 15–29 m L/min: reduce dose by 50% or increase dosing interval to every 6–8 hours. For GFR <15 m L/min: use with caution, reduce dose by 75% or administer every 8–12 hours. Hemodialysis: no supplemental dosing; not dialyzable.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% or extend interval to every 6 hours. Child-Pugh Class C: avoid use; if necessary, reduce dose by 75% and monitor closely.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Children ≥12 years: 0.5–2 mg intravenously or intramuscularly every 3–4 hours as needed. Children 2–12 years: 0.1–0.2 mg/kg/dose intravenously or intramuscularly every 3–4 hours as needed (max single dose 2 mg). Children <2 years: not recommended.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Elderly patients (≥65 years): initiate at 0.5 mg intravenously or intramuscularly every 4–6 hours; increase cautiously based on response and tolerability. Reduce total daily dose by 25–50% compared to younger adults.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and risk of abuse and dependence.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Concomitant use with CNS depressants (e.g., benzodiazepines) increases risk of sedation, respiratory depression, coma, and death,Risk of respiratory depression, especially in elderly, cachectic, or debilitated patients,Physical and psychological dependence with chronic use,May increase intracranial pressure in patients with head injury,Risk of hypotension in hypovolemic patients,May impair ability to perform hazardous tasks,Use in renal or hepatic impairment requires dose adjustment
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Known hypersensitivity to butorphanol or any component,Patients with significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
No significant food interactions. Avoid alcohol consumption.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Pregnancy Category C. First trimester: No adequate studies; potential risk based on animal data at 2.5-5 times human dose. Second trimester: Same as first; prolonged use may lead to neonatal opioid withdrawal syndrome. Third trimester: Risk of neonatal respiratory depression if administered near term; may cause opioid withdrawal in newborn after chronic use.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Excreted in human milk in low concentrations; M/P ratio not established. American Academy of Pediatrics considers butorphanol compatible with breastfeeding. Caution with high doses or prolonged use due to potential for neonatal drowsiness or withdrawal.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No specific dose adjustments established; pharmacokinetics may be altered (increased volume of distribution, decreased peak concentrations). Use lowest effective dose for shortest duration; avoid during labor if alternative available due to risk of neonatal respiratory depression.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Stadol (butorphanol) preservative-free is for IV/IM use only; not intended for epidural or intrathecal administration due to potential neurotoxicity from the formulation. Onset of analgesia is rapid (within minutes IV). Butorphanol has ceiling effect on respiratory depression, making it safer than full mu agonists in equianalgesic doses. It can cause dysphoric reactions, especially in opioid-naive patients. Use with caution in patients with hepatic or renal impairment.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
This medication can cause drowsiness, dizziness, or lightheadedness; avoid driving or operating heavy machinery until you know how it affects you.,Do not drink alcohol or take other central nervous system depressants (e.g., benzodiazepines, other opioids) while using this medicine.,Report any severe nausea, vomiting, confusion, or hallucinations to your healthcare provider.,Butorphanol can be habit-forming; use only as prescribed.,If you are pregnant, plan to become pregnant, or are breastfeeding, inform your doctor before use.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STADOL PRESERVATIVE FREE vs ACEPHEN, answered by our medical review team.
STADOL PRESERVATIVE FREE is a Opioid Analgesic that works by Butorphanol is a synthetic agonist-antagonist opioid analgesic that exerts its effects primarily through binding to kappa-opioid receptors and, to a lesser extent, mu-opioid receptors, producing analgesia and sedation. It also has partial antagonist activity at mu receptors.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STADOL PRESERVATIVE FREE and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STADOL PRESERVATIVE FREE is: 0.5–2 mg intravenously or intramuscularly every 3–4 hours as needed for pain. Alternatively, 1–2 mg as a single dose, may repeat in 30–60 minutes if needed.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STADOL PRESERVATIVE FREE and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STADOL PRESERVATIVE FREE is classified as Category C. Pregnancy Category C. First trimester: No adequate studies; potential risk based on animal data at 2.5-5 times human dose. Second trimester: Same as first; prolonged use may lead t. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.